Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,455,800 | 2,962,600 | 3,118,100 | 2,506,400 | 1,995,800 |
| Marketable Securities | 5,538,800 | 5,791,100 | 5,487,100 | 5,937,200 | 5,473,800 |
| Receivables | 6,565,400 | 5,731,000 | 5,741,100 | 5,687,100 | 5,610,000 |
| Inventories | 3,084,300 | 3,103,600 | 3,200,800 | 3,254,400 | 3,205,600 |
| TOTAL | $18,446,000 | $18,209,200 | $18,021,900 | $17,980,700 | $16,859,500 |
| Non-Current Assets | |||||
| PPE Net | 5,458,900 | 5,266,100 | 5,120,400 | 5,002,300 | 4,840,700 |
| Investments And Advances | 9,828,300 | 9,786,000 | 10,260,600 | 10,285,700 | 10,058,200 |
| Intangibles | 1,309,800 | 1,286,900 | 1,257,400 | 1,380,900 | 1,351,700 |
| Other Non-Current Assets | 6,687,600 | 6,320,600 | 5,898,400 | 5,519,800 | 5,109,100 |
| TOTAL | $23,284,600 | $22,659,600 | $22,536,800 | $22,188,700 | $21,359,700 |
| Total Assets | $41,730,600 | $40,868,800 | $40,558,700 | $40,169,400 | $38,219,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,159,300 | 1,027,100 | 939,000 | 903,800 | 723,900 |
| Accrued Expenses | 2,966,500 | N/A | 2,876,400 | N/A | N/A |
| Other current liabilities | N/A | 2,724,400 | N/A | 2,975,700 | 2,461,200 |
| TOTAL | $5,530,600 | $5,107,700 | $4,368,400 | $4,425,100 | $3,667,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,986,600 | 1,986,200 | 1,985,900 | 1,985,500 | 1,985,100 |
| Deferred Revenues | 684,800 | 636,200 | 553,000 | 545,600 | 481,900 |
| Other Non-Current Liabilities | 2,281,600 | 2,126,200 | 2,018,800 | 1,861,800 | 1,701,900 |
| TOTAL | $4,488,600 | $4,337,500 | $4,933,400 | $4,786,500 | $4,613,300 |
| Total Liabilities | $10,019,200 | $9,445,200 | $9,301,800 | $9,211,600 | $8,280,300 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 102,955 | 104,839 | 105,720 | 105,100 | 105,987 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 37,621,400 | 36,423,800 | 35,797,100 | 35,045,800 | 33,680,200 |
| Other shareholders' equity | -35,700 | 12,400 | 77,700 | 68,600 | 52,800 |
| TOTAL | $31,711,400 | $31,423,600 | $31,256,900 | $30,957,800 | $29,938,900 |
| Total Liabilities And Equity | $41,730,600 | $40,868,800 | $40,558,700 | $40,169,400 | $38,219,200 |